Visual Acuity

This third installment of the current state of LASIK looks at more data and thoughts about the future.

Patients with neurotrophic keratitis who underwent treatment with Oxervate in a real-world setting experienced favorable improvements in corneal sensation, visual acuity and stability of the corneal epithelium, according to a speaker at the virtual American Society of Cataract and Refractive Surgery meeting.

In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, Alice Epitropoulos, MD, discusses her study examining visual acuity results in patients implanted with the enVista toric IOL (Bausch + Lomb).

A post hoc analysis of a subset of patients with diabetic macular edema treated with an anti-VEGF agent in the VISTA phase 3 trial identified a moderate correlation between significant reductions in macular retinal nonperfusion with improvements in best corrected visual acuity and central retinal thickness, according to a presenter at the virtual Association for Research in Vision and Ophthalmology meeting.

ATLANTA — Physicians have noted that steadily increasing digital device use among children is becoming a significant health issue, and optometrists have found patterns linking extensive screen time and altered visual acuity, according to a presenter at SECO.

Early “optimistic” data are available for the first two patients receiving Lineage Cell Therapeutics’ thaw-and-inject formulation of OpRegen via a new subretinal delivery system, according to a press release.

Changes in central subfield thickness may account for only a low percentage of total variations in visual acuity changes, according to findings published in JAMA Ophthalmology.

SAN FRANCISCO — Patients with age-related macular degeneration could successfully self-operate an optical coherence tomography device at home, according to study findings presented at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting.

SAN FRANCISCO — Treatment with Beovu resulted in visual acuity letter gains among patients with age-related macular degeneration and polypoidal choroidal vasculopathy, according to a presentation at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting. “Most of you have heard that in the last week, Beovu (brolucizumab, Novartis) was approved by the FDA to treat neovascular AMD,” Glenn J. Jaffe, MD, Robert Machemer Professor of Ophthalmology and Chief of the Vitreoretinal Division at Duke Eye Center, said during his presentation. “We know from clinical trials that it is effective for typical AMD.”

A 63-year-old Native American female was referred to the electrodiagnostics clinic for an OCT, ERG and visual-evoked potential, if needed, due to the patient’s unexplained decreased vision. She was best corrected to 20/50 OD, OS.